Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Endometrial Neoplasms · Ovarian Neoplasms · Pancreatic Neoplasms · Biliary Tract Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 540 (planned)
- Started
- Jul 19, 2021
- Main results expected
- Apr 2027
- Fully finished
- Apr 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy
Measured over: Cycle 1 (21 Days)
Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents
Measured over: Cycle 1 (21 Days)
Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab
Measured over: Estimated up to 2 years
To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab
Measured over: Estimated up to 2 years
To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation
Measured over: Estimated up to 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04956640 · record last updated 2026-05-29 · checked 2026-11-09 15:36 UTC